Supplementary Table S1: Predictors of annual eGFR change among older PWH: A sensitivity analysis with inclusion of selected variables with posterior probability <30% on BMA

Characteristics of participants	Unadjusted estimates (95%CI), p-value	Posterior probability	Multivariable adjusted estimates (95%CI), p-value
Age (per decade)	0.22 (-0.77, 1.21), 0.66	2.60%	0.94 (-0.04, 1.92), 0.06
Female	1.55 (0.66, 2.44), <0.01	**94.20%**	**1.29 (0.37, 2.21), 0.01**
Diastolic BP (per 10 mmHg)	0.04 (-0.30, 0.38), 0.81	1.50%	0.20 (-0.24, 0.64), 0.38
Systolic BP (per 10 mmHg)	-0.12 (-0.33, 0.08), 0.24	3.20%	-0.23 (-0.50, 0.04), 0.09
BMI (per kg/m2)	-0.05 (-0.14, 0.05), 0.34	5.60%	
NSAIDS	1.28 (-0.36, 2.91), 0.13	2.30%	
At least one NCD	-0.46 (-1.35, 0.44), 0.32	3.60%	
Hypertension	-0.55 (-1.45, 0.35), 0.23	11.70%	
Diabetes mellitus	-1.43 (-3.07, 0.20), 0.09	4.40%	-1.01 (-2.70, 0.68), 0.24
Stroke	0.42 (-3.25, 4.09), 0.82	1.60%	
Ever used tobacco	-0.29 (-1.30, 0.72), 0.57	4.80%	
Current alcohol use	-1.01 (-2.06, 0.04), 0.06	3.80%	
Prior diagnosis of TB	-0.51 (-1.43, 0.41), 0.28	1.60%	-0.39 (-1.32, 0.54), 0.41
HBV surface antigen positive	2.75 (0.34, 5.16), 0.03	**99.70%**	**4.66 (2.59, 6.73), <0.01**
CD4 T-lymphocyte (per 100cells/ml higher)	0.23 (0.07, 0.38), <0.01	28.60%	**0.21 (0.04, 0.37), 0.01**
Viral load ≥50 HIV RNA copies/ml	-1.10 (-2.36, 0.17), 0.09	2.70%	-0.61 (-1.81, 0.59), 0.32
Years on ART	-0.03 (-0.13, 0.07), 0.57	1.40%	
TDF-based regimen	0.44 (-0.79, 1.67), 0.49	2.40%	
Abacavir-based regimen	0.12 (-1.49, 1.74), 0.88	1.40%	
Protease inhibitors	-1.87 (-2.99, -0.75), <0.01	1.90%	
Integrase strand transfer inhibitors	2.20 (1.23, 3.18), <0.01	**100.00%**	**2.35 (1.35, 3.34), <0.01**
Ever TDF use	-0.40 (-1.97, 1.17), 0.62	1.50%	
TDF switch	0.61 (-0.39, 1.61), 0.23	2.40%	
TDF duration	-0.02 (-0.14, 0.09), 0.67	2.00%	
TDF status at baseline:			
Current TDF vs. never	1.43 (-0.88, 3.74), 0.23	2.10%	
Recent TDF vs. never	0.14 (-2.79, 3.07), 0.92	9.20%	
Past TDF vs. never	1.76 (-1.11, 4.63), 0.23	1.40%	
Dipstick Proteinuria	-0.10 (-0.49, 0.30), 0.63	2.20%	-0.12 (-1.61, 1.36), 0.87

Adjusted estimates are from a mixed effects linear regression model with random intercepts and slopes estimated following selection of variables by Bayesian model averaging (BMA). BMI (Body mass index) and viral load are time updated, all the other covariates are taken from baseline: PWH, People with HIV; eGFR, estimated glomerular filtration rate; BP, Blood Pressure; TB, Tuberculosis; HBV, Hepatitis B virus; NCD, Non-communicable disease; NSAIDS, Non-steroidal anti-inflammatory drugs; TDF, Tenofovir disoproxil fumarate; ART, Antiretroviral therapy; RNA, Ribonucleic acid.

Supplementary Table S2: Predictors of annual eGFR change among older PWH: A sensitivity analysis performed after inverse probability weighting.

Characteristics of participants	Unadjusted estimates(95%CI), p-value	Posterior probability	Multivariable adjusted estimates(95%CI), p-value
Age (per decade)	0.22 (-0.77, 1.21), p=0.66	3.2%	
Female	1.55 (0.66, 2.44), p<0.01	**93.7%**	**1.56 (0.64, 2.48), p<0.01**
DBP (per 10 mmHg)	0.04 (-0.30, 0.38), p=0.81	1.6%	
SBP (per 10 mmHg)	-0.12 (-0.33, 0.08), p=0.24	3.1%	
BMI (per kg/m2)	-0.05 (-0.14, 0.05), p=0.34	4.2%	
NSAIDS	1.28 (-0.36, 2.91), p=0.13	1.9%	
At least one NCD	-0.46 (-1.35, 0.44), p=0.32	4.5%	
Hypertension	-0.55 (-1.45, 0.35), p=0.23	15.2%	
Diabetes mellitus	-1.43 (-3.07, 0.20), p=0.09	4.5%	
Stroke	0.42 (-3.25, 4.09), p=0.82	1.7%	
Ever used tobacco	-0.29 (-1.30, 0.72), p=0.57	4.5%	
Current alcohol use	-1.01 (-2.06, 0.04), p=0.06	2.7%	
Prior TB diagnosis	-0.51 (-1.43, 0.41), p=0.28	1.6%	
Hepatitis B	2.75 (0.34, 5.16), p=0.03	**100.0%**	**4.34 (2.24, 6.43), p<0.01**
CD4 (/100)	0.23 (0.07, 0.38), p<0.01	**39.4%**	**0.20 (0.04, 0.37), p=0.02**
Viral load Detectable (>50 HIV RNA copies/ml)	-1.10 (-2.36, 0.17), p=0.09	**2.4%**	
Years on ART	-0.03 (-0.13, 0.07), p=0.57	1.4%	
TDF-based regimen	0.44 (-0.79, 1.67), p=0.49	2.7%	
Abacavir-based regimen	0.12 (-1.49, 1.74), p=0.88	1.7%	
Protease inhibitors	-1.87 (-2.99, -0.75), p<0.01	2.0%	
Integrase strand transfer inhibitors	2.20 (1.23, 3.18), p<0.01	**100.0%**	**2.58 (1.61, 3.56), p<0.01**
Ever TDF use	-0.40 (-1.97, 1.17), p=0.62	**1.7%**	
TDF switch	0.61 (-0.39, 1.61), p=0.23	3.4%	
TDF duration	-0.02 (-0.14, 0.09), p=0.67	2.0%	
TDF status at baseline:			
Current TDF vs. never	1.43 (-0.88, 3.74), p=0.23	2.6%	
Recent TDF vs. never	0.14 (-2.79, 3.07), p=0.92	14.3%	
Past TDF vs. never	1.76 (-1.11, 4.63), p=0.23	1.4%	
Proteinuria	-0.10 (-0.49, 0.30), p=0.63	2.1%	

Adjusted estimates are from linear mixed models with random intercepts and slopes with adjustment of estimates using inverse probability of censoring weighted (IPCW) analysis, BMI (Body mass index) and viral load are time-updated. All other covariates are taken from the baseline visit: PWH, People with HIV; eGFR, estimated glomerular filtration rate; BP, Blood Pressure; TB, Tuberculosis; HBV, Hepatitis B virus; NCD, Non-communicable disease; NSAIDS, Non-steroidal anti-inflammatory drugs; TDF, Tenofovir disoproxil fumarate; ART, Antiretroviral therapy; RNA, Ribonucleic acid.

Supplementary Table S3: Predictors of rapid kidney function loss when adjusting for baseline eGFR among older PWH

Baseline characteristics	Rapid eGFR loss, n (%) 76 (15.2%)	Unadjusted RR (95% CI)	P-value	Adjusted RR (95%CI)	P-value
eGFR at baseline (mls/min/1.73m^2)	89 (73-96)	1.02 (1.01-1.04)	<0.01	1.04 (1.02-1.05)	**<0.01**
Age in years	65 (62-74)	1.03 (0.69-1.52)	0.90	1.00 (0.95-1.05)	0.88
Male gender	50 (66)	1.82 (1.17-2.83)	0.01	1.68 (0.97-2.88)	0.06
Diastolic BP (per 10mmHg)	81 (74-89)	0.97 (0.84-1.13)	0.73	0.87 (0.69-1.09)	0.23
Systolic BP (per 10mmHg)	137 (121-152)	1.05 (0.97-1.14)	0.23	1.11 (0.96-1.27)	0.15
BMI (kg/m^2)	23.9 (21.6-28.2)	1.00 (0.96-1.04)	0.98	1.03 (0.99-1.09)	0.10
NSAIDS use	2 (3)	0.54 (0.14-2.06)	0.36	0.51 (0.23-1.14)	0.10
At least one NCD	62 (82)	1.00 (0.64-1.56)	0.99	1.39 (0.16-12.02)	0.77
Hypertension	61 (80)	1.36 (0.80-2.30)	0.26	0.74 (0.09-6.37)	0.78
Diabetes	13 (17)	1.27 (0.74-2.18)	0.39	0.75 (0.39-1.43)	0.38
Stroke	1 (1)	0.82 (0.13-5.20)	0.83	1.08 (0.26-4.40)	0.92
Smoking (past and current)	18 (24)	0.99 (0.61-1.61)	0.95	0.64 (0.39-1.04)	0.07
Current alcohol use	27 (36)	1.42 (0.92-2.17)	0.11	1.20 (0.77-1.86)	0.42
Prior diagnosis of TB	33 (44)	1.34 (0.88-2.03)	0.17	1.14 (0.72-1.80)	0.59
HBV surface antigen positive	2 (3)	0.62 (0.16-2.35)	0.48	0.33 (0.09-1.17)	0.09
CD4 T-lymphocytes (per 100cells/ml higher)	548 (376-729)	0.85 (0.78-0.93)	<0.01	0.91 (0.84-0.99)	**0.04**
Viral load ≥50 HIV RNA copies/ml	6 (8)	1.09 (0.67-1.77)	0.74	0.91 (0.45-1.86)	0.80
Years on ART	13 (9-16)	0.99 (0.94-1.04)	0.53	0.98 (0.93-1.03)	0.44
Abacavir based regimen	15 (20)	1.54 (0.93-2.55)	0.1	1.55 (0.71-3.39)	0.27
Protease inhibitor-based regimen	21 (28)	1.67 (1.07-2.62)	0.03	0.91 (0.50-1.66)	0.77
Integrase strand transfer inhibitor-based regimen	35 (46)	0.45 (0.30-0.68)	<0.01	0.51 (0.29-0.90)	**0.02**
TDF duration (log_2TDF years)	5.5 (3.9-9.6)	1.17 (0.95-1.42)	0.14	1.47 (1.21-1.78)	**<0.01**
Switched from TDF during cohort	17 (24)	0.98 (0.58-1.64)	0.93	1.88 (1.09-3.24)	**0.02**
Switched from TDF prior cohort enrollment	14 (19)	1.48 (0.86-2.53)	0.16	2.36 (1.00-5.59)	0.05
Proteinuria (≥30mg/dl (+))	14 (18)	1.37 (0.79-2.27)	0.24	1.25 (0.74-2.13)	0.40

Estimates are from a modified Poisson regression model adjusted for baseline eGFR: PWH, People with HIV; eGFR, estimated glomerular filtration rate; RR, Risk Ratio; BP, Blood Pressure; TB, Tuberculosis; HBV, Hepatitis B virus; NCD, Non-communicable disease; NSAIDS, Non-steroidal anti-inflammatory drugs; TDF, Tenofovir disoproxil fumarate; ART, Antiretroviral therapy; RNA, Ribonucleic acid; BMI, Body mass index.